Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIO-RAD LABORATORIES, INC.

(BIO)
  Report
Delayed Nyse  -  04:03 2022-12-02 pm EST
419.06 USD   +0.24%
11/17Bio-Rad Expands Range of Quality Controls for Abbott Clinical Diagnostics Platforms
AQ
11/08Transcript : Bio-Rad Laboratories, Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-08-2022 11:00 AM
CI
11/08Bio-rad Laboratories, Inc. : Regulation FD Disclosure (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Credit Suisse Initiates Coverage of 20 Companies in Life Science Tools, Services, Diagnostics Sectors; Outperform-Rated Bio-Rad, IQVIA, Bipo-Techne, Natera Named Top Picks

08/25/2022 | 10:17am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ADAPTIVE BIOTECHNOLOGIES CORPORATION 3.58% 8.96 Delayed Quote.-68.07%
BIO-RAD LABORATORIES, INC. 0.24% 419.06 Delayed Quote.-44.54%
BIO-TECHNE CORPORATION -1.99% 84.69 Delayed Quote.-34.52%
ILLUMINA, INC. -0.95% 218.76 Delayed Quote.-41.95%
INVITAE CORPORATION -4.38% 2.84 Delayed Quote.-81.40%
IQVIA HOLDINGS INC. -1.28% 217.73 Delayed Quote.-22.83%
NATERA, INC. 1.43% 41.84 Delayed Quote.-55.20%
All news about BIO-RAD LABORATORIES, INC.
11/17Bio-Rad Expands Range of Quality Controls for Abbott Clinical Diagnostics Platforms
AQ
11/08Transcript : Bio-Rad Laboratories, Inc. Presents at Credit Suisse 31st Annual..
CI
11/08Bio-rad Laboratories, Inc. : Regulation FD Disclosure (form 8-K)
AQ
11/07Bio-Rad Laboratories, Inc. and NuProbe USA Enter Into an Exclusive Licensing Agreement ..
CI
11/01Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare C..
AQ
10/31Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare C..
BU
10/28BIO-RAD LABORATORIES, INC. Management's Discussion and Analysis of Financial Condition..
AQ
10/28Bio-Rad Laboratories Posts Lower Q3 Net Income, Revenue; Shares Fall Friday
MT
10/28Credit Suisse Adjusts Bio-Rad Laboratories' Price Target to $640 From $715, Keeps Outpe..
MT
10/27Bio-rad : Q3 Earnings Snapshot
AQ
More news
Analyst Recommendations on BIO-RAD LABORATORIES, INC.
More recommendations
Financials (USD)
Sales 2022 2 820 M - -
Net income 2022 - - -
Net cash 2022 857 M - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 12 425 M 12 425 M -
EV / Sales 2022 4,10x
EV / Sales 2023 3,88x
Nbr of Employees 7 900
Free-Float 70,5%
Chart BIO-RAD LABORATORIES, INC.
Duration : Period :
Bio-Rad Laboratories, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-RAD LABORATORIES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 419,06 $
Average target price 596,67 $
Spread / Average Target 42,4%
EPS Revisions
Managers and Directors
Norman D. Schwartz Chairman, President & Chief Executive Officer
Ilan Daskal Chief Financial Officer & Executive Vice President
Andrew J. Last Chief Operating Officer & Executive Vice President
Jeffrey L. Edwards Independent Director
Gregory K. Hinckley Chief Financial Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
BIO-RAD LABORATORIES, INC.-44.54%12 425
ABBOTT LABORATORIES-23.20%188 463
MEDTRONIC PLC-23.39%105 909
BECTON, DICKINSON AND COMPANY2.06%71 518
DEXCOM, INC.-12.01%45 621
HOYA CORPORATION-18.03%36 935